relationship was found to exist. Serum protein binding of CAP was also evaluated (43.7 ± 5.7% bound; N = 24). Differences in CAP binding did not apparently account for a significant portion of the variability in the observed saliva/serum CAP concentration ratios. The degree of variation observed indicated that saliva CAP concentrations could not be relied upon for the prediction of serum CAP concentrations.
Utilization of chloramphenicol (CAP), the first broad-spectrum antibiotic, has fluctuated markedly during its 30-year history. Occasional occurrence of potentially fatal aplastic anemia (20) , coupled with the discovery of ampicillin, resulted in a dramatic decline in the popularity of this antibiotic. Recently, an increased frequefxcy of ampicillin-resistant Haemophilus influenzae (1) and an appreciation of the activity of CAP against anaerobic infections (8) have led to a resurgence of use of this drug.
Dose-related toxicities consist of reversible bone marrow suppression, which occurs at serum concentrations above 25 ,ug/ml (17, 19, 24) , and the gray syndrome, consisting of cardiovascular collapse, respiratory depression, and coma, which has been reported in neonates (3, 15, 21, 22) , infants (5), and adults (14, 22) with serum concentrations ranging from 40 to 200 ,ug/ml. Because of these potential toxicities and marked interpatient variability of metabolism and elimination of CAP, it is desirable to monitor serum CAP concentrations during therapy.
The use of drug concentrations in saliva as a guide to therapy with potentially toxic medications has been extensively investigated. The reader is referred to the excellent reviews of Horning et al. (11) and Danhof and Breimer (6) . Excellent correlations have been reported between serum and saliva concentrations of theophylline in normal volunteers (13) and in ambulatory patients (7, 8) . This correlation deteriorates markedly, however, in acutely ill hospitalized patients (10 evaluate the potential of saliva drug concentration monitoring in the patient population most likely to receive a given drug.
To date only one paper has been published regarding the distribution of CAP into saliva (2) . These authors investigated CAP saliva and serum concentrations following the administration of a 1-g intravenous dose of CAP to normal subjects and patient volunteers. Potential problems with this study included the use of a single dose, which may not represent multiple-dose conditions, subjects who were not acutely ill, and a microbiological assay ofquestionable specificity and precision. The mean saliva-to-serum concentration ratio reported by these authors was 0.14. There was marked intersubject variability of this ratio.
It was the goal of this study to investigate the relationship between serum and saliva CAP concentrations, to determine the effect of serum protein binding of CAP on this relationship, and to evaluate the utility of saliva CAP concentration monitoring as a guide to therapy.
MATERIALS AND METHODS
Twenty hospitalized adult patients being treated with CAP in whom a serum CAP assay had been ordered by their physician were studied. Patients were receiving either intravenous CAP succinate or oral capsules of CAP. They represented a wide spectrum of medical conditions. The drug was given in various dosages as determined by their physician. CAP concentrations were determined at least 24 h after initiation of therapy, 4 to 6 h after the previous dose. Five milliliters of blood was collected by venipuncture into glass Vacutainer tubes. A simultaneous saliva sample was collected from the patient after stimulating flow with citric acid crystals. This compound stimulates on June 25, 2017 by guest http://aac.asm.org/ Downloaded from flow and electrolyte secretion of both parotid and submaxillary glands to a similar extent (16) . The degree of stimulation varied between patients, and variable volumes of saliva were collected (0.5 to 3.0 ml). Samples were immediately centrifuged and stored at -4°C until analysis. A total of 27 sample pairs were evaluated.
Analysis of total CAP concentration in all samples was performed by high-performance liquid chromatography (12) . The method has been shown to be specific for CAP in the presence of metabolites, succinate ester, and other antibiotics. The analytic procedure was as follows: 0.1 ml of the sample was shaken with an equal volume of 0.1 N sodium acetate buffer (pH 4.6). This solution was extracted with 1 ml of ethyl acetate containing 12.5 ,ug of 5-ethyl-5-p-tolylbarbituric acid (99+%; Aldrich Chemical Co. Inc., Milwaukee, Wis.) per ml as an internal standard. The organic phase was evaporated to dryness under a nitrogen stream at 40°C. The residue was redissolved with 0.2 ml of methanol, and 0.02 ml of this solution was injected into the chromatograph. Separation was accomplished by using a 25-cm C-18 fL-Bondapak column (PN-27324; Waters Associates, Milford, Mass.) at 400C. The mobile phase was 25% acetonitrile (Photrex grade; J. T. Baker Chemical Co., Phillipsburg, N.J.) in pH 6.0, 0.1 N acetate buffer. Ultraviolet absorbance of CAP and the internal standard were determined at 270 nm. Retention times for CAP and the internal standard were 3.0 and 4.8 min, respectively. The procedure demonstrated a between-day coefficient of variation of 12.7% on 7.5-ug/ml and 6.1% on 25-,ug/ml control samples.
CAP binding was determined in the serum of 24 of the 27 samples. Binding was also determined on nine occasions using control adult serum to demonstrate the between-run variability of the binding procedure. Equilibrium dialysis was performed by placing 0.3 ml of serum and 0.3 ml of phosphate-buffered physiological saline spiked with 30 Various correlations were evaluated. The correlation between total serum and saliva CAP concentration was significant (R = 0.80, P < 0.001) (Fig. 1) . The correlation between free serum and saliva CAP concentrations was also significant (R = 0.81, P < 0.001). There was no significant correlation between percentage bound and the saliva/serum concentration ratio or between the total serum concentration and the saliva/serum concentration ratio. The distribution of the saliva/serum concentration ratio values was apparently not normal (standard deviation was large compared to the mean and mode, 0.0 to 0.5, was not equal to the mean, 0.25).
DISCUSSION
The extreme variability observed in serum CAP concentrations obtained 4 to 6 h after dosing is consistent with previous observations (17) and supports the need for individualization of therapy with this drug by monitoring serum concentration. It would appear, however, that saliva concentrations in specimens collected under the conditions of this study do not consistently reflect serum concentrations. Our binding results were similar to those reported by Grafnetterova et al. (9) . Using an equilibrium dialysis procedure comparable to the one employed in the present study, these authors found 50.8 ± 0.7% CAP binding in the sera of 15 normal subjects. Interpatient variability of CAP binding to serum proteins was miniimal and did not contribute significantly to observed variability in the serum/saliva concentration ratios. This conclusion is based upon the negligible improvement in correlation (0.80 to 0.81) achieved when free serum CAP concentration rather than total concentration was correlated with saliva CAP concentration. Phenytoin, which is highly but variably bound to serum proteins, demonstrates a greater correlation between free serum and saliva concentrations than between total serum and saliva concentrations (4) . The low and relatively constant binding of CAP observed in this study (43.7 ± 5.7%) would not be expected to be a major source of variation in the saliva-to-serum drug concentration ratio.
The possibility that the non-normal distribution of the saliva/serum concentration ratio data observed in our study could have resulted from poor assay sensitivity was investigated. Poor sensitivity would tend to produce lower than expected saliva concentrations when serum concentrations, and thus saliva concentrations, are low. We therefore divided our results into two VOL. 15, 1979 on June 25, 2017 by guest http://aac.asm.org/ Downloaded from ANTIMICROB. AGENTS CHEMOTHER. (2) . Their serum and saliva concentration data obtained at 1 and 2 h postdose were chosen for comparison (N = 31). The serum concentrations obtained in these specimens were similar to those obtained in our study (mean, 9.6; standard deviation, 4.21). Their saliva/serum concentration ratio data demonstrated marked interpatient variability (mean ratio, 0.14; range, 0.0 to 0.45). Comparison of our ratio data with those of Bender et al. using the Wilcoxon rank sum test revealed no significant differences (P > 0.10).
The dependence of the correlation between serum and saliva CAP concentrations on the two high serum CAP concentration values (30.5 and 31.3) seen in Fig. 1 was also evaluated. When these data were omitted, the degree of correlation decreased (R = 0.41) but remained significant (P < 0.05).
In conclusion, it would appear that under the conditions of the present study serum and saliva CAP concentrations are significantly but variably related, and that differences in the binding of CAP to serum proteins does not account for the variability of this relationship. Furthermore, it would appear that, whereas a statistically significant correlation between serum and saliva CAP concentrations exists, the variability observed precludes reliance upon saliva CAP concentration as a guide to therapy. 
